Rare
lephants
Screener
Toggle theme
CytomX Therapeutics, Inc.
CTMX
·
Healthcare, Drug Manufacturers - General, United States
Financial Statements
Profitability
Balance Sheet
Cash Flow
Price Ratios
Share-Based Metrics
Valuation
Cash Flow History
Net Cash Flow Breakdown
Net Cash Flow
Cash Flow
›
Net Cash Flow Breakdown
Net Cash Flow Breakdown
Chart
Table
FY2020
FY2017
FY2014
Total Cash from Operations:
$31.7M
Line Item
Value
% of Total
Capital Expenditures
$2.3M
7.3%
Other Investing
$16.4M
51.8%
Working Capital
$9.5M
30.1%
Net Cash Flow
$3.4M
10.8%
Download CSV
